Overview

Study of ONO-8539 in Patients With Overactive Bladder

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate efficacy, safety and tolerability of ONO-8539 in patients with overactive bladder.
Phase:
Phase 2
Details
Lead Sponsor:
Ono Pharmaceutical Co. Ltd
Treatments:
Tolterodine Tartrate